SCHEMBL1730877

SCHEMBL1730877

CS(=O)(=O)c1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 4/20 0.58
MAP4K4 O95819 4/20 0.58
MAPK8 P45983 4/20 0.58
MAPK9 P45984 4/20 0.58
CSNK1A1 P48729 4/20 0.58
GSK3B P49841 4/20 0.58
CSNK1G2 P78368 4/20 0.58
PRKD2 Q9BZL6 4/20 0.58
CSNK1G1 Q9HCP0 4/20 0.58
CSNK1G3 Q9Y6M4 4/20 0.58
MAPK1 P28482 3/20 0.58
GSK3A P49840 3/20 0.58
TAOK1 Q7L7X3 3/20 0.58
MINK1 Q8N4C8 3/20 0.58
CSNK1D P48730 3/20 0.58
CLK4 Q9HAZ1 2/20 0.58
MAPK13 O15264 1/20 0.58
LCK P06239 1/20 0.58
LYN P07948 1/20 0.58
AKT2 P31751 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969778 0.89 PRKD3 (0.52) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL12023544 0.81 CSNK1E (0.64) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL3519701 0.81 MAPK9 (0.58) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL12023386 0.81 PRKD3 (0.61) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL1728799 0.81 CSNK1E (0.65) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL12154383 0.81 MAPK9 (0.70) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL3524010 0.81 PRKD3 (0.59) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL3522612 0.81 MAPK9 (0.58) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL1730222 0.81 PTGS2 (0.66) PRKD3MAP4K4MAPK8MAPK9CSNK1A1
SCHEMBL3524969 0.80 CSNK1E (0.71) PRKD3MAP4K4MAPK8MAPK9CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483166-B1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA INST SCI & TECH (KR) 2023-11-01 EP disclosed
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-05-17 US disclosed
EP-3845539-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Korea Institute of Science and Technology (KR) 2021-07-07 EP disclosed
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-04-30 US disclosed
US-10570155-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-02-25 US disclosed
US-20190211032-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-07-11 US disclosed
EP-3483166-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Korea Institute of Science and Technology (KR) 2019-05-15 EP disclosed
US-20110301160-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. (US) 2011-12-08 US disclosed
US-20110301160-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. (US) 2011-12-08 US disclosed
US-20110301160-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. (US) 2011-12-08 US disclosed
EP-1633758-B1 IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 ARQULE INC (US) 2011-11-23 EP disclosed
EP-1633758-B1 IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 ARQULE INC (US) 2011-11-23 EP disclosed
US-7902192-B2 Inhibitors of P38 and methods of using the same ARQULE, INC. (US) 2011-03-08 US disclosed
US-7902192-B2 Inhibitors of P38 and methods of using the same ARQULE, INC. (US) 2011-03-08 US disclosed
US-7902192-B2 Inhibitors of P38 and methods of using the same ARQULE, INC. (US) 2011-03-08 US disclosed
EP-2251343-A1 IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS ARQULE, INC. (US) 2010-11-17 EP disclosed
EP-2251343-A1 IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS ARQULE, INC. (US) 2010-11-17 EP disclosed
US-20070270418-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. 2007-11-22 US disclosed
US-20070270418-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. 2007-11-22 US disclosed
US-20070270418-A1 Inhibitors of P38 and Methods of Using the Same ARQULE, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131199-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME TPMT, MYD88, IDO1 PRKD3 1507/4885MAP4K4 2650/4885MAPK8 3370/4885
US-10570155-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same TPMT, MYD88, IDO1 PRKD3 1507/4885MAP4K4 2650/4885MAPK8 3370/4885
US-11332479-B2 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same TPMT, MYD88, IDO1 PRKD3 1507/4885MAP4K4 2650/4885MAPK8 3370/4885
US-20190211032-A1 IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME TPMT, MYD88, IDO1 PRKD3 1507/4885MAP4K4 2650/4885MAPK8 3370/4885
US-20070270418-A1 Inhibitors of P38 and Methods of Using the Same MAPK1, MAPK8, MAPK7 PRKD3 541/4885MAP4K4 44/4885MAPK8 2/4885
US-20110301160-A1 Inhibitors of P38 and Methods of Using the Same MAPK1, MAPK7, MAPK8 PRKD3 507/4885MAP4K4 43/4885MAPK8 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.